原发性肺癌患者循环中的造血祖细胞。
Circulating hematopoietic progenitors in patients with primary lung cancer.
作者信息
Shimizu E, Mukai J N, Takaue Y, Ogura T
机构信息
Third Department of Internal Medicine, University of Tokushima School of Medicine.
出版信息
Jpn J Cancer Res. 1990 Dec;81(12):1293-9. doi: 10.1111/j.1349-7006.1990.tb02693.x.
The levels of circulating hematopoietic progenitors were measured in 28 patients with primary lung cancer. The average numbers of progenitors per milliliter of blood were 33 (range 0-360) for colony-forming unit-granulocyte macrophage (CFU-GM), 23 (range 0-140) for burst-forming unit-erythrocyte (BFU-E), and 4 (range 0-50) for colony-forming unit-mixed lineages (CFU-mix). No significant influence of age, sex, histological type, or clinical stage of the tumor on the progenitor levels was detected. After cytoreductive chemotherapy of the patients by treatment with cisplatin plus etoposide, the cells showed 6- to 50-fold rebound overshoots, but no rebound was observed after treatment with cisplatin alone, cisplatin plus mitomycin C or cisplatin plus vindesine plus mitomycin C, or in 4 of 5 patients treated with cyclophosphamide plus adriamycin plus vincristine. Peripheral blood hematopoietic progenitors should be useful as an alternative source of stem cells for lung cancer patients treated with marrow ablative chemotherapy.
对28例原发性肺癌患者的循环造血祖细胞水平进行了检测。每毫升血液中祖细胞的平均数量如下：集落形成单位-粒细胞巨噬细胞（CFU-GM）为33（范围0 - 360），爆式红系集落形成单位（BFU-E）为23（范围0 - 140），混合谱系集落形成单位（CFU-mix）为4（范围0 - 50）。未检测到年龄、性别、肿瘤组织学类型或临床分期对祖细胞水平有显著影响。在用顺铂加依托泊苷对患者进行细胞减灭化疗后，细胞出现了6至50倍的反弹超调，但在单独使用顺铂、顺铂加丝裂霉素C、顺铂加长春地辛加丝裂霉素C治疗后，以及在5例接受环磷酰胺加阿霉素加长春新碱治疗的患者中有4例未观察到反弹。外周血造血祖细胞作为接受骨髓清除性化疗的肺癌患者干细胞的替代来源应是有用的。
Zotero 插件